Slayback Pharma
Princeton
About Slayback Pharma
Slayback is founded on the principle of “connecting the dots”. This principle translates into their philosophy of connecting one idea with another. The idea is to conceptualize and develop complex generic and specialty drugs. They focus on products that are challenging and highly complex to develop and/or manufacture. It could be a complex oil-in-water emulsion or a sterile long acting injectable using nano-spheres or sterile suspensions with complex particle physics. They have also worked on complex hormonal products with challenging cross-contamination issues. They aim to optimize the use of technology and potential (generated from a strong experience in this field) to develop a value proposition for their customers. Through this process of drug development, they remotely aim at reducing the cost of therapy by bringing expensive branded drugs within the reach of patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $110.0M
- Funding stage: M&A
- Last round: Series B (Jan 2020)
- Website: slayback-pharma.com
- Phone: 609-945-3443
Industries & Categories
Biopharma, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/slayback-pharma-18657 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.